This post is presented by our media partner Psychedelic News Wire
View the original article here.
Researchers from Compass Pathways PLC (NASDAQ: CMPS) have commenced the largest-ever phase 3 clinical trial investigating the effectiveness of psilocybin against depression. The mental health company first announced the phase 3 program in late 2022 during an online Capital Markets Day.
Compass Pathways’ phase 2b study on the therapeutic potential of psilocybin against depression provided encouraging results and allowed the company to move forward with the next phase of research. Like the recently commenced phase 3 trial, the phase 2b study made history as the largest double-blind, controlled and randomized study of psilocybin therapies.
It showed that patients with depression could experience a “significant reduction” in the symptoms of depression within three weeks of taking a single COMP360 psilocybin dose. This phase of research was designed to grant scientists a deeper understanding of the safety and efficiency of a single 25 or 10 mg COMP360 psilocybin dose compared to a 1 mg dose of a conventional depression treatment.
A few months after the completion of this phase, Compass Pathways announced that it was scheduled to begin the third phase of clinical trials. The ongoing phase 3 clinical trial is now looking into the efficiency, tolerability and safety of using psilocybin as a therapy for treatment-resistant depression.
Psilocybin is part of a group of compounds called hallucinogenics that have recently captured the scientific community’s attention due to their therapeutic potential. After being outlawed for decades, psychedelics have exhibited the potential to treat numerous mental disorders in initial studies.
The research being carried out by companies such as Compass Pathways will potentially pave the way to adopting psychedelic therapies into current mental health treatment protocols. Compass Pathways began recruiting participants for its COMP 005 trial in late 2022 and began tests in January 2023 with 378 participants.
The study is looking to compare the effects of taking a 25 mg dose of synthetic psilocybin alongside psychological support with taking a placebo and is expected to wind down in October 2024. The mental health care company then began enrolling participants for its second COMP 006 study this February.
This study will involve 568 participants taking either 1 mg, 10 mg or 25mg of COMP360 at random with the aim of determining if a second dose of psilocybin can expand the pool of people who reported positive responses in comparison to the phase 2b study.
It is also designed to determine if repeated 10 mg doses of COMP350 can deliver a “meaningful treatment response” and is expected to end by May 2025.
About PsychedelicNewsWire
PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.
To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.psychedelicnewswire.com
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.psychedelicnewswire.com/Disclaimer
Do you have questions or are you interested in working with PNW? Ask our Editor
PsychedelicNewsWire (PNW)
San Francisco, California
www.psychedelicnewswire.com
415.949.5050 Office
Editor@PsychedelicWire.com
PsychedelicNewsWire is part of the InvestorBrandNetwork.
This post was originally published by our media partner here.
